Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options

被引：24

作者：

Elit, Laurie ^{[1
,2
]}

Hirte, Hal ^{[2
]}

机构：

[1] McMaster Univ, Dept Obstet & Gynecol, Hamilton, ON L8V 5C2, Canada

[2] McMaster Univ, Dept Oncol, Hamilton, ON L8V 5C2, Canada

来源：

ONCOTARGETS AND THERAPY | 2013年 / 6卷

关键词：

ovarian cancer; systemic therapy; biologic agents; PEGYLATED LIPOSOMAL DOXORUBICIN; PLATINUM-BASED CHEMOTHERAPY; PHASE-II TRIAL; EPIDOXORUBICIN PLUS PACLITAXEL; RANDOMIZED CONTROLLED-TRIAL; SINGLE-AGENT PACLITAXEL; PRIMARY PERITONEAL; DOUBLE-BLIND; OPEN-LABEL; 2ND-LINE THERAPY;

D O I：

10.2147/OTT.S30238

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Objectives: To review the available systemic treatments for women with recurrent ovarian cancer. Methods: A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews. Results: We discuss the efficacy and toxicity outcomes associated with systemic therapy for platinum-sensitive and platinum-resistant ovarian cancer. Clearly, platinum-based combination systemic therapy shows a prolonged progression-free interval compared with single-agent chemotherapy with a low toxicity profile. No clear superior management strategy exists for platinum-resistant/refractory disease. Novel targeted antiangiogenic agents (eg, bevacizumab), angiopoeitin inhibitors (eg, AMG 386), and poly ADP ribose polymerase inhibitors (eg, olaparib) are reviewed. Conclusion: Although combination platinum-based chemotherapy has shown benefits for women with platinum-sensitive recurrent ovarian cancer, the optimal treatment strategy for those with platinum-resistant or platinum-refractory disease is not clear. Molecular and genetic targeted therapies may provide opportunities for those women with tumor profiles that show sensitivity for specific agents.

引用

页码：107 / 118

页数：12

共 67 条

[1] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[2] Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200) [J].

Alberts, David S. ;

Liu, P. Y. ;

Wilczynski, Sharon P. ;

Clouser, Mary C. ;

Lopez, Ana Maria ;

Michelin, David P. ;

Lanzotti, Victor J. ;

Markman, Maurie .

GYNECOLOGIC ONCOLOGY, 2008, 108 (01) :90-94

[3]

[Anonymous], J CLIN ONCOL

[4]

[Anonymous], JCO S

[5]

[Anonymous], 2012, CAN CANC STAT 2012

[6]

[Anonymous], J CLIN ONCOL

[7]

Audeh MW, 2009, J CLIN ONCOL, V27

[8] Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity [J].

Azad, Nilofer S. ;

Posadas, Edwin M. ;

Kwitkowski, Virginia E. ;

Steinberg, Seth M. ;

Jain, Lokesh ;

Annunziata, Christina M. ;

Minasian, Lori ;

Sarosy, Gisele ;

Kotz, Herbert L. ;

Premkumar, Ahalya ;

Cao, Liang ;

McNally, Deborah ;

Chow, Catherine ;

Chen, Helen X. ;

Wright, John J. ;

Kohn, Elise C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3709-3714

[9] A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy [J].

Baumann, K. H. ;

du Bois, A. ;

Meier, W. ;

Rau, J. ;

Wimberger, P. ;

Sehouli, J. ;

Kurzeder, C. ;

Hilpert, F. ;

Hasenburg, A. ;

Canzler, U. ;

Hanker, L. C. ;

Hillemanns, P. ;

Richter, B. ;

Wollschlaeger, K. ;

Dewitz, T. ;

Bauerschlag, D. ;

Wagner, U. .

ANNALS OF ONCOLOGY, 2012, 23 (09) :2265-2271

[10] A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study [J].

Biagi, J. J. ;

Oza, A. M. ;

ChalChal, H. I. ;

Grimshaw, R. ;

Ellard, S. L. ;

Lee, U. ;

Hirte, H. ;

Sederias, J. ;

Ivy, S. P. ;

Eisenhauer, E. A. .

ANNALS OF ONCOLOGY, 2011, 22 (02) :335-340

← 1 2 3 4 5 6 7 →